Literature DB >> 21876062

Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels.

Ping Lu1, Anna C Haagsma, Hoang Pham, Janneke J Maaskant, Selena Mol, Holger Lill, Dirk Bald.   

Abstract

Pyrazinoic acid, the active form of the first-line antituberculosis drug pyrazinamide, decreased the proton motive force and respiratory ATP synthesis rates in subcellular mycobacterial membrane assays. Pyrazinoic acid also significantly lowered cellular ATP levels in Mycobacterium bovis BCG. These results indicate that the predominant mechanism of killing by this drug may operate by depletion of cellular ATP reserves.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21876062      PMCID： PMC3195041          DOI： 10.1128/AAC.00507-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  40 in total

Review 1.  Respiratory ATP synthesis: the new generation of mycobacterial drug targets?

Authors:  Dirk Bald; Anil Koul
Journal:  FEMS Microbiol Lett       Date:  2010-03-20       Impact factor: 2.742

2.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

Authors:  Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona
Journal:  Lancet       Date:  2010-05-22       Impact factor: 79.321

3.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

4.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Authors:  W McDERMOTT; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-10

5.  Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Y Zhang; A Scorpio; H Nikaido; Z Sun
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

6.  Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.

Authors:  O Zimhony; J S Cox; J T Welch; C Vilchèze; W R Jacobs
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

Review 7.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Authors:  Julian G Hurdle; Alex J O'Neill; Ian Chopra; Richard E Lee
Journal:  Nat Rev Microbiol       Date:  2011-01       Impact factor: 60.633

8.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

9.  Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase.

Authors:  Anna C Haagsma; Ioana Podasca; Anil Koul; Koen Andries; Jerome Guillemont; Holger Lill; Dirk Bald
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

10.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Authors:  Kevin Pethe; Patricia C Sequeira; Sanjay Agarwalla; Kyu Rhee; Kelli Kuhen; Wai Yee Phong; Viral Patel; David Beer; John R Walker; Jeyaraj Duraiswamy; Jan Jiricek; Thomas H Keller; Arnab Chatterjee; Mai Ping Tan; Manjunatha Ujjini; Srinivasa P S Rao; Luis Camacho; Pablo Bifani; Puiying A Mak; Ida Ma; S Whitney Barnes; Zhong Chen; David Plouffe; Pamela Thayalan; Seow Hwee Ng; Melvin Au; Boon Heng Lee; Bee Huat Tan; Sindhu Ravindran; Mahesh Nanjundappa; Xiuhua Lin; Anne Goh; Suresh B Lakshminarayana; Carolyn Shoen; Michael Cynamon; Barry Kreiswirth; Veronique Dartois; Eric C Peters; Richard Glynne; Sydney Brenner; Thomas Dick
Journal:  Nat Commun       Date:  2010-08-24       Impact factor: 14.919
View more
  21 in total

1.  Pyrazinamide Is Active against Mycobacterium tuberculosis Cultures at Neutral pH and Low Temperature.

Authors:  Alice L den Hertog; Sandra Menting; Richard Pfeltz; Matthew Warns; Salman H Siddiqi; Richard M Anthony
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 2.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

3.  Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Authors:  Kathy Williams; Austin Minkowski; Opokua Amoabeng; Charles A Peloquin; Dinesh Taylor; Koen Andries; Robert S Wallis; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

4.  Differences in Interactions of Benzoic Acid and Benzoate with Interfaces.

Authors:  Benjamin J Peters; Allison S Groninger; Fabio L Fontes; Dean C Crick; Debbie C Crans
Journal:  Langmuir       Date:  2016-09-08       Impact factor: 3.882

5.  Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria.

Authors:  Wendy Balemans; Luc Vranckx; Nacer Lounis; Ovidiu Pop; Jérôme Guillemont; Karen Vergauwen; Selena Mol; Ron Gilissen; Magali Motte; David Lançois; Miguel De Bolle; Kristien Bonroy; Holger Lill; Koen Andries; Dirk Bald; Anil Koul
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

6.  Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

Authors:  Nicole C Ammerman; Rosemary V Swanson; Elaine M Bautista; Deepak V Almeida; Vikram Saini; Till F Omansen; Haidan Guo; Yong Seok Chang; Si-Yang Li; Asa Tapley; Rokeya Tasneen; Sandeep Tyagi; Fabrice Betoudji; Chivonne Moodley; Bongani Ngcobo; Logan Pillay; Linda A Bester; Sanil D Singh; Richard E Chaisson; Eric Nuermberger; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

7.  Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.

Authors:  Wei Li; Ashutosh Upadhyay; Fabio L Fontes; E Jeffrey North; Yuehong Wang; Debbie C Crans; Anna E Grzegorzewicz; Victoria Jones; Scott G Franzblau; Richard E Lee; Dean C Crick; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

8.  Uncoupling Environmental pH and Intrabacterial Acidification from Pyrazinamide Susceptibility in Mycobacterium tuberculosis.

Authors:  Nicholas D Peterson; Brandon C Rosen; Nicholas A Dillon; Anthony D Baughn
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

9.  Antiinfectives targeting enzymes and the proton motive force.

Authors:  Xinxin Feng; Wei Zhu; Lici A Schurig-Briccio; Steffen Lindert; Carolyn Shoen; Reese Hitchings; Jikun Li; Yang Wang; Noman Baig; Tianhui Zhou; Boo Kyung Kim; Dean C Crick; Michael Cynamon; J Andrew McCammon; Robert B Gennis; Eric Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

10.  Tuning the composition of AuPt bimetallic nanoparticles for antibacterial application.

Authors:  Yuyun Zhao; Chunjie Ye; Wenwen Liu; Rong Chen; Xingyu Jiang
Journal:  Angew Chem Int Ed Engl       Date:  2014-05-14       Impact factor: 15.336
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.